A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Metabolic syndrome; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 02 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 15 Mar 2017 Status changed from planning to not yet recruiting.
    • 16 Nov 2016 According to a ProMetic Life Sciences media release, company has received clearance by Health Canada to commence this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top